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Transforming growth factor b (TGFb) can inhibit the invitro proliferation, survival and differentiation
of B cell progenitors, mature B lymphocytes and plasma cells. Here we demonstrate unexpected, age-
dependent reductions in the bone marrow (BM) B cell progenitors and immature B cells in TGFb1
2/2
mice. To evaluate TGFb responsiveness during normal B lineage development, cells were cultured in
interleukin 7 ðIL7Þ ^ TGFb: Picomolar doses of TGFb1 reduced pro-B cell recoveries at every
timepoint. By contrast, the pre-B cells were initially reduced in number, but subsequently increased
compared to IL7 alone, resulting in a 4-fold increase in the growth rate for the pre-B cell population.
Analysis of puriﬁed BM sub-populations indicated that pro-B cells and the earliest BP1
2 pre-B cells
were sensitive to the inhibitory effects of TGFb1. However, the large BP1
þ pre-B cells, although
initially reduced, were increased in number at days 5 and 7 of culture. These results indicate that
TGFb1 is importantfor normalB cell development invivo,and that B cell progenitors are differentially
affected by the cytokine according to their stage of differentiation.
Keywords: B cell progenitor; Bone marrow; IL7; Pre-B cell; Pro-B cell; TGFb
Abbreviations: BM, bone marrow; HC, antibody heavy chain; BCP, B cell progenitor; TGFb,
transforming growth factor b; IL7, interleukin 7; LM, littermate
INTRODUCTION
Transforming growth factor b (TGFb) is distinguished
among cytokines in its involvement in multiple biological
processes, eliciting unique responses according to context
(Massague et al., 1992; Rifkin et al., 1993; McCartney-
Francis and Wahl, 1994; Bottinger et al., 1997). Its
overlappingfunctionsincluderegulationofembryogenesis
(Dicksonetal.,1995;Kaartinenetal.,1995;Bonyadietal.,
1997; Sanford et al., 1997), cell cycle and viability (Ravitz
and Wenner, 1997; Hocevar and Howe, 1998) and cellular
adhesion (Roberts et al., 1992; Wahl, 1994; Kim and
Yamada, 1997; Letterio and Roberts, 1998). The interplay
of these TGFb-regulated processes controls the develop-
ment and function of the immune system (Yaswen et al.,
1996; Letterio and Roberts, 1998; Larsson et al., 2001).
Limitations to studying TGFb effects in vivo
are imposed by its importance during embryogenesis.
Gene-targeting of each isoform (TGFb1, 2 or 3) as well as
each of the two receptor subunits (TbRI and TbRII)
results in lethality at or prior to birth (Dickson et al., 1995;
Kaartinen et al., 1995; Martin et al., 1995; Bonyadi et al.,
1997; Sanford et al., 1997). The earliest lethality is seen in
TbRI
2/2,T bRII
2/2 (Larsson et al., 2001), and in ,50%
of TGFb1
2/2 embryos (Shull et al., 1992; Kulkarni et al.,
1993), which expire at ,10.5 days post-coitus, due to
aberrantly developed yolk sac vasculature and anemia.
The embryonic anemia in vivo is likely a secondary result
of inadequate vascularization, since endothelia from the
TGFb1 mutant embryos fail to differentiate in culture
(Martin et al.,1995), whereas invitro development of yolk
sac-derived TbRI
2/2 hematopoietic progenitors into
various blood cell lineages is similar to controls (Larsson
et al., 2001).
The importance of TGFb in immune regulation is
underscored by the phenotype of TGFb1
2/2 mice, which
have multiple abnormalities, including systemic inﬂam-
mation to which they succumb by 3–5 weeks after birth
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et al., 1993; Diebold et al., 1995; Kulkarni et al., 1995;
McCartney-Francis et al., 1997). The inﬂammatory
disease of TGFb1
2/2 mice is attenuated when T cells
are eliminated, implicating T cells as a major mediator of
inﬂammation(KulkarniandKarlsson,1993;Dieboldetal.,
1995; Kulkarni et al., 1995; Borkowski et al., 1996;
Letterio et al., 1996; McCartney-Francis et al., 1997;
Nakabayashi et al., 1997; Kobayashi et al., 1999;
McLennan et al., 2000).
Once a hematopoietic progenitor enters the B lineage
pathway, it progresses through a number of developmental
stages deﬁned by expression of cell surface differentiation
antigens (Hardy et al., 1991; Rolink et al., 1999), cell
cycle status (Osmond, 1991; Itoh et al., 1996), antibody
variable region gene rearrangements (Hardy et al., 1991;
Hardy, 1992; Li et al., 1993; Papavasiliou et al., 1997;
Rolink et al., 1999), responsiveness to and requirements
for interleukin 7 (IL7) receptor signaling (Peschon et al.,
1994; Candeias et al., 1997; Marshall et al., 1998) and
interaction with the bone marrow (BM) stroma (King
et al., 1988; Gimble et al., 1989; Dittel et al., 1993; Dittel
and LeBien, 1995; Borghesi et al., 1997). The IL7
receptor is indispensable for mouse B cell development
during the V-to-DJ heavy chain (HC) variable region gene
rearrangement process (Corcoran et al., 1998). Acqui-
sition of mHC and formation of the pre-B cell receptor are
associated with a decreased IL7 dose-response threshold
(Marshall et al., 1998). The resulting increases in IL7
sensitivity may be responsible for the large size and
mitotic status of early/intermediate pre-B cells. Late pre-B
cells exit the cell cycle and undergo light chain V–J
rearrangement in preparation for full antibody assembly
and surface expression on the more differentiated B cell
(Meffre et al., 2000; Melchers et al., 2000).
The effects of exogenous TGFb have been examined in
cultured B lineage cells representative of almost every
developmental stage, and are usually inhibitory. Early
studies showed that TGFb inhibits the proliferative
response of BM B cell progenitors (BCP) to IL7, and
that it can inhibit kLC acquisition in a differentiating B
lineage cell line (Lee et al., 1987; Kincade et al., 1989).
Similar observations have been made for k light chains in
human fetal BM cultures (Rehmann and LeBien, 1994).
However, these studies did not distinguish the effects of
TGFb on pro-B versus pre-B cells within one system.
Induction of the transcriptional regulator Id3 by TGFb,
together with inhibition of cell cycling and Rag1 mRNA
expression has also been demonstrated (Kee et al., 2001).
TGFb effects at later mature B and plasma cells stages are
almost exclusively negative with the exception of
inducing IgA isotype switching (Kim and Kagnoff,
1990; Lebman et al., 1990; Shockett and Stavnezer,
1991). These studies indicate that TGFb can inhibit the
in vitro survival, proliferation and differentiation of
antibody-producing B cells at all stages of development.
An inhibitory role for TGFb in the immune system is
supported by the phenotype of juvenile TGFb1
2/2 mice
(Christ et al., 1994). Inﬁltrates of plasma cells are found in
secondary lymphoid organs and also in non-lymphoid
tissues where they accompany inﬂammatory inﬁltrates of
other hematopoietic cells (Christ et al., 1994; Kulkarni
et al., 1995; van Ginkel et al., 1999). The mice also have
increased levels of anti-nuclear and anti-collagen serum
antibodies (Dang et al., 1995; Yaswen et al., 1996) and
hyperproliferation in the splenic B cell follicles (Christ
et al., 1994).
These observations, together with the described
inhibitory effects of TGFb on invitro B cell development,
predicted the expansion of B cell progenitors in the
absence of TGFb invivo. We found instead an age-related
deﬁciency in B cell development in TGFb1
2/2 mice. The
complication of the co-existing inﬂammatory disease in
these mice lead us to re-examine the in vitro effects of
TGFb1 on deﬁned sub-populations of normal BM B
lineage cells. The results of this combined approach
indicate that deﬁciencies in the earliest B cell progenitors
in the TGFb1
2/2 mice are likely to be due to secondary
effects of the phenotype, since pro-B cell growth is
i n h i b i t e db yT G F b1 in vitro. By contrast, TGFb1
increases the recovery of the large pre-B cells.
Collectively, these observations demonstrate that TGFb1
is required for normal B cell development in vivo, and
indicate differential sensitivity of B cell progenitors to
TGFb according to their stage of differentiation.
MATERIALS AND METHODS
Flow Cytometry
TGFb1
2/2 mice were derived from TGFb1
þ/2 crosses as
described (Kulkarni et al., 1993). Erythrocyte-depleted
BM cells were recovered from TGFb1
2/2 mice and aged-
matched TGFb1
þ/þ littermate controls on a mixed
C57BL/6J £ SVJ/129 background. All incubations for
ﬂow cytometry were on ice for 15min, followed by
washing with 1% FBS in PBS. Aliquots of 10
6cells from
each mouse were stained with combinations of ﬂuoro-
chrome-conjugated antibodies speciﬁc for CD43 (S7),
BP1 (6C3/BP1), HSA (M1/69), Mac1 (M1/70), Thy1.2
(30H12) and B220 (RA3-6B2) from BD Pharmingen (San
Diego, CA), IgD (SBA-1) and goat anti-mouse IgM from
Southern Biotechnology Associates (Birmingham, AL).
Stained cells were analyzed using a Becton-Dickinson
FACSCalibur ﬂow cytometer (San Diego, CA).
Values from TGFb1
þ/þ and TGFb1
2/2 mice were
compared using a Student’s t-Test.
Cell Culture
Erythrocyte-depleted BM from 4- to 5-week-old female
C57BL/6 mice was puriﬁed by centrifugation over a
Lympholyte M gradient (Cedar Lane, Hornby, Ont.,
Canada). B220
þ cells were isolated by positive selection
with magnetic beads (Miltenyi, Auburn, CA); sorting
D.A. KAMINSKI et al. 86efﬁciency was assessed by ﬂow cytometry to be 85 ^ 8%.
FACS
w-sorted cells were puriﬁed with a MoFlo ﬂow
cytometer (Cytomation, Fort Collins, CO) using anti-
CD19 (clone 6D5 from Southern Biotechnology Associ-
ates, Birmingham, AL), anti-BP1 and anti-IgM (as above).
5 £ 10
4 sorted cells/ml were plated in complete IMDM
(5% FCS, 5 £ 10
25M 2ME, 1% each L-glutamine,
penicillin/streptomycin, non-essential amino acids) and
treated with 10ng/ml recombinant mouse IL7 (PeproTech,
Rocky Hill, NJ) ^ recombinant human TGFb1 (R and D
Systems, Minneapolis, MN). Two doses of 0.04ng/ml
(1.6pM) or 1ng/ml (40pM) were compared in all of the
experiments shown here because dose-response exper-
iments showed distinct read-outs at these two concen-
trations. Harvested cells were counted by Trypan Blue
exclusion and surface-stained for B220 (as above) and
sIgM [goat anti-mouse IgM
cy5 from Jackson Laboratories
(Bar Harbor, ME) or MB86
Alexa647 from John Kearney
(Birmingham, AL)], or control antibodies. These cells
were ﬁxed in 1% paraformaldehyde, permeablized with
Tween 20 and stained intracellularly with a goat anti-
mouse m
F antibody. For some experiments, the CytoFix/
Cytoperm kit from Pharmingen was used according to
the manufacturer’s instructions. The pre-B cell growth
rate was calculated as (pre-B cell number recovered
on day 7 2 pre-B cell number recovered on day 3)/4
days ¼ cells/day.
RESULTS
Age-dependent BM B Lineage Cell Reductions in
TGFb1
2/2 Mice
Flow cytometry was used to examine the proportions
(Fig. 1A,B) and absolute numbers (Fig. 1C) of B220
þ B
lineage cells in the BM of neonatal (1.5-week-old) and
juvenile (3.5-week-old) TGFb1
2/2 mice. The 1.5 week-
old TGFb1
2/2 mice were comparable to the TGFb1
þ/þ
littermate (LM) controls at the early, sIgM
2 and later,
sIgM
þ stages. By contrast, 3.5-week-old mice showed a
signiﬁcant 2.6-fold reduction in the percentage of
B220
þsIgM
2 cells, corresponding to a signiﬁcant 4.6-
fold reduction in absolute cell number. Absolute numbers
and percentages of B220
þsIgM
þ B cells were also
reduced, although not consistently.
The cell surface marker system described by Hardy
et al. (1991) was used to further deﬁne the B lineage
developmental stages affected by the TGFb1 deﬁciency,
and the results were calculated both as a percentage of
total BM (Fig. 2A,B) and as absolute cell numbers
( F i g .2 C ) .I nT G F b1
2/2 mice examined at 3.5
weeks of age, the percentage of cells in Fraction B
(B220
þCD43
þHSA
þBP1
2), including pro- and pre-B
cells (Wasserman et al., 1997), was not signiﬁcantly
changed,althoughtheabsolutenumbersofthesecellswere
2.6-fold reduced. The percentage and absolute number of
pre-B cells in Fraction C (B220
þCD43
þHSA
þBP1
þ)
FIGURE 1 B cell development in TGFb1
2/2 mice. BM from
TGFb1
2/2 mice and age-matched TGFb1
þ/þ (LM) controls was
prepared for ﬂow cytometry as indicated in “Methods” section.
(A) Proﬁles of gated lymphocytes showing expression of B220 and
sIgM. Values indicated are the per cent of total BM. (B) Percentage of
total BM for individual mice. *p ¼ 0:0001 for the B220
þsIgM
2 BCP
between TGFb1
2/2 and LM controls. (C) Absolute numbers of cells for
the populations shown in A and B. **p ¼ 0:008:
TGFb AND B CELL DEVELOPMENT 87FIGURE 2 B cell progenitor deﬁciencies in juvenile TGFb1
2/2 BM. BM lymphocytes from 3.5-week-old TGFb1
2/2 mice and LM controls were
prepared for ﬂow cytometry as in Fig. 1 using the indicated markers. (A) Representative ﬂow cytometry proﬁles gated on the B220
þCD43
þ or
B220
þCD43
2 lymphocyte populations as indicated. Values indicated are the per cent of total BM. (B) Percentage of total BM for individual mice.
*p # 0:001 between TGFb1
2/2 and LM controls. (C) Absolute numbers of B lineage cells for mice represented in A and B. **p # 0:02 between
TGFb1
2/2 and LM controls.
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fold, respectively. The late pre-B cells in Fraction D
(B220
þCD43
2IgM
2IgD
2) were proportionally
reduced by 4.6-fold and in absolute cell number by 8.2-
fold. The subsequent immature B cells, Fraction E
(B220
þCD43
2IgM
þIgD
2) were proportionally reduced
by 5.7-fold and in absolute number by 9.2-fold. Mature B
cells (B220
þCD43
2IgM
þIgD
þ, Fraction F) in the BM
were variably increased or decreased in proportion and in
absolute number (Fig. 2C) as was observed in the
periphery [not shown and Christ et al. (1994)]. It should be
noted that Fraction A (B220
þCD43
þHSA
2BP1
2) is not
consistently affected in the TGFb1
2/2 mice (Fig. 2A and
not shown); however, not all the cells in this population
are progenitors of the B lineage (Tudor et al., 2000).
In vivo, the reductions seen in Fraction B were
statistically signiﬁcant when calculated as absolute
numbers of cells recovered (2.6-fold), but not as a
percentage of total BM cells. This might suggest that
Fraction B itself is unchanged, and that the smaller size of
the TGFb1
2/2 mice (Shull et al., 1992; Boivin et al.,
1995; Kulkarni et al., 1995), and therefore smaller bone
cavity, is the cause of this reduction in cell number.
However, normalizing the cell number to body weight of
each mouse still results in a signiﬁcant reduction in
Fraction B, although the degree of reduction is less, at 1.8-
fold (þ/þ, 1:46 £ 104 ^ 4:98 £ 103 cells=g; 2/2, 8:08 £
103 ^ 2:27 £ 103 cells=g; p ¼ 0:048). The reduction in
Fraction C, however, is signiﬁcant regardless of how the
data are calculated: as a proportion of total BM (3.0-fold),
as an absolute cell number (5.0-fold), and also as a
normalized cell number [3.6-fold (þ/þ, 2:90 £ 103 ^
632cells=g; 2/2, 810 ^ 463cells=g; p ¼ 0:00091)].
A summary of a more extensive analysis of mice at
different ages is shown in Table I as the frequency of
TGFb1
2/2 mice with reductions of $2-fold in the
absolute numbers of BM B lineage cells. These mice are
not included in Fig. 2 because a different number of bones
per mouse were used for the analysis. Although there is
some variability, these results conﬁrm the age-dependent
decrease in BCP in the TGFb1
2/2 mice. The frequencies
of mature B cells are reduced in slightly more than half of
the mice, which may be due to variable experiences of
these recirculating cells in the periphery. Phenotypic
variability in TGFb1
2/2 mice has been noted in other
contexts, for example, inﬂammation in organs other than
heart and lung (Shull et al., 1992; Kulkarni and Karlsson,
1993; Boivin et al., 1995; Kulkarni et al., 1995).
Activated T cells are responsible for much of the
characteristic inﬂammatory phenotype of the TGFb1
2/2
mouse (Diebold et al., 1995; Kobayashi et al., 1999).
To ask whether the BCP reductions in the TGFb1
2/2
mice were associated with an altered BM microenviron-
ment, Thy1.2 and Mac1 were used as markers for BM T
and myeloid cells, respectively. Although the Thy1.2
þ
population was proportionally increased in all 3.5-week-
old mice examined (Fig. 3A), this did not correlate with
increased cell numbers in most mice (Fig. 3B). The
proportions of Mac1
þ cells were increased in half of the
mice examined (Fig. 3C); however, once again, this
generally did not correspond to an increase in the absolute
numbers of myeloid lineage cells (Fig. 3D). One
explanation for the observed discrepancy between the
percentages and absolute cell numbers may again be the
smaller size of the TGFb1
2/2 mice (Shull et al., 1992;
Boivin et al., 1995; Kulkarni et al., 1995). However, when
the data were normalized to body weight, a similar pattern
was observed for Thy1.2 (þ/þ, 1:8 £ 104 ^ 1:1 £
104 cells=g; 2/2, 4:4 £ 104 ^ 2:6 £ 104 cells=g), and
for Mac1 (þ/þ, 7:5 £ 104 ^ 1:1 £ 104 cells=g; 2/2,
11:1 £ 104 ^ 4:8 £ 104 cells=g). These ﬁndings show that
there is an altered cellular composition of the BM in the
TGFb1
2/2 mice, including changes in the proportions of
TABLE I Frequency* of BM B lineage compartment reductions in TGFb1
2/2 mice
B220
+ B Lineage fraction†
Age sIgM
2 sIgM
+ BC DEF
1–2 weeks 1/7 1/7 0/4 0/4 1/7 1/7 3/7
.2 weeks 10/14 3/14 7/11 10/13 11/12 9/12 7/12
*Number of TGFb1
2/2 mice with reductions in absolute cell numbers of $2-fold compared to LM controls per number of TGFb1
2/2 mice examined.
†According to (Hardy et al., 1991; Li et al., 1993; Li et al., 1996).
FIGURE 3 Tand myeloid cell compartments of TGFb1
2/2 BM. Flow
cytometry analysis of 3.5-week-old TGFb1
2/2 mice and controls was
performed using the markers indicated. Proportions (A,C) and absolute
numbers (B,D) of bone marrow cells expressing T (Thy1.2; A,B) and
myeloid (Mac1; C,D) lineage markers are shown. The Thy 1.2
þ cells are
within the lymphoid gate. p . 0:05 for all sample sets.
TGFb AND B CELL DEVELOPMENT 89myeloid and T lineage cells. However, the absolute
numbers of these cells are not consistently increased in all
of the mice that had an equally severe reduction in BCP.
Therefore, a global disruption of the BM microenviron-
ment seems unlikely, although our analysis does not
exclude possible inhibitory effects of inﬂammatory/
myelopoieticfociontheBlineagecellsinTGFb1
2/2 BM.
Exogenous TGFb1 Effects upon Normal Pro- and
Pre-B Cells In Vitro
The complex pathology of the TGFb1
2/2 mice and the
lack of correlation between the frequency of Thy1.2
þ and
Mac1
þ BM cells and the BCP deﬁciency lead us to
re-examine the effects of TGFb1 on B cell development in
vitro. We asked whether TGFb1 might be beneﬁcial for B
cell development as suggested by the phenotype of the
TGFb1
2/2 mice. B220
þ BM B lineage cells from normal
(C57BL/6) mice were treated with TGFb1 in the presence
of IL7, a cytokine that stimulates BCP proliferation prior
to the late pre-B cell stage (Hardy et al., 1991; Marshall
et al., 1998). Stromal cells were not included in our system
due to their ability to produce and respond to TGFb (Dittel
et al., 1993; Dittel and LeBien, 1995; Robledo et al., 1998;
Olsen et al., 2001).
Intracellular (i.c.) mHC expression in B220
þsIgM
2
BCP was used to identify pre-B cells recovered from
cultures of IL7-stimulated B220
þ BM cells (Fig. 4A).
At day 3 in the control sample of IL7 alone (ﬁrst column),
therewas a predominance of pre-B cells; however, the pro-
B cell-enriched population (i.c. mHC
2 BCP) predomi-
nated by day 7. It should be noted that a majority of the
pre-B cells in the starting population are late pre-B cells,
which do not proliferate in response to IL7 (Hardy et al.,
1991; Marshall et al., 1998). During the course of a week-
long culture, these cells should either expire or mature to
become sIgM
þ B cells and thus be excluded from the
analysis. Meanwhile, IL7-responsive pro-B cells accumu-
late and predominate in the cultures by day 7.
Addition at day 0 of either 0.04 or 1ng/ml TGFb1 to the
IL7 cultures resulted in little change at day 3 in the
percentage of pre-B cells compared to IL7 alone (Fig. 4A).
However, both treatments resulted in a consistent
reduction in the total viable cell numbers recovered (not
shown) corresponding to a 2-fold reduction in both pro-
and pre-B cell numbers at day 3 of culture [Fig. 4B
(Bottom) and C, respectively].
At the later timepoints of 5 and 7 days, TGFb1
treatment resulted in a small increase in the proportion of
pre-B cells in comparison to IL7 alone (Fig. 4A). This was
partially due to reductions in pro-B cell numbers in the
presence of TGFb1 (Fig. 4B). In contrast to reductions in
pre-B cell numbers seen at day 3 of culture, treatment with
0.04ng/ml TGFb1 resulted in a modest increase in the
numbers of pre-B cells recovered at 5 and 7 days. By
contrast, treatment with 1ng/ml TGFb1 showed minor
pre-B cell reductions at later timepoints (Fig. 4C).
The initial reductions in pre-B cells indicate that some
cells are likely to be sensitive to the inhibitory effects of
TGFb1. However, the remaining pre-B cell population
either has, or acquires a very high proliferative capacity,
indicated by a signiﬁcant 4-fold increase in the rate of
growth between 3 and 7 days (Fig. 4D).
To identify the populations responsible for these distinct
outcomes, we initiated similar experiments using sort-
puriﬁed BM. The BP1 cell surface marker was used to
subdivide normal BM into two sub-populations of
CD19
þsIgM
2 BCP: (1) BP1
2 cells, ,60% of which are
i.c. mHC
þ and (2) large BP1
þ cells, ,90–99% i.c. mHC
þ
(not shown). Between days 3 and 7 in culture with IL7
alone, the number of BP1
2-derived pro- and pre-B cells
increased (Fig. 5A,B, respectively); in each case and at all
time points, 0.04 and 1ng/ml exogenous TGFb1 resulted
in reduced cell recovery. TGFb1-mediated reductions in
pro-B cell recoveries were also conﬁrmed using CD19
þ
Rag1
2/2 BM as a source of pro-B cells (not shown).
In contrast to the cell growth observed with IL7 alone in
cultures of BP1
2 BCP, the large BP1
þ pre-B cells
decreased in number between days 3 and 7 (Fig. 5C). In
this context, treatment with either dose of TGFb1 resulted
in an initial decrease in pre-B cell recoveries, but
subsequently, low-dose TGFb1 treatment resulted in a
net increase at days 5 and 7 of culture (2.1 ^ 0.7 and
3.0 ^ 0.6-fold increase, respectively over IL7 alone;
n ¼ 3 experiments).
Figure 5D summarizes the effects of low-dose TGFb1
treatment where the diameter of each circle relative to the
control (1.0) represents the average fold change in cell
number. As seen on day 3, each stage analyzed contains
cells that are sensitive to the inhibitory effects of TGFb1.
TGFb1-mediated reductions continue over time for BP1
2
BCP-derived pro- and pre-B cells, whereas the BP1
þ
fraction contains cells that are positively affected by
exogenous TGFb1 treatment at a low-dose (0.04ng/ml).
At a later timepoint in the culture, IgM
þ B cells
accumulate as well (Fig. 5D and data not shown).
DISCUSSION
We have demonstrated an age-dependent reduction in BM
B lineage cells in TGFb1
2/2 mice. The deﬁciency is
apparent as early as Hardy’s Fraction B, containing pro-B
cells and extends through the immature B cell stage. The
mice also have variable increases in the proportions and
numbers of BM Thy1.2
þ and Mac1
þ cells, but these do
not consistently correlate with the reduction in B lineage
cells. Subsequent studies of the in vitro effects of
exogenous TGFb1 on BM B lineage cells from normal
mice showed reductions in pro-B cell recoveries as early
as day 3 and continuing through day 7 of incubation at
pg/ml doses of TGFb1. Although the same cultures
showed an initial decrease in pre-B cell numbers, this was
followed by increases at days 5 and 7 translating into a
4-fold increase in the rate of growth for the pre-B cell
D.A. KAMINSKI et al. 90population. By sort-puriﬁcation of the starting BCP
subpopulations, the large BP1
þ pre-B cell fraction was
identiﬁed as containing the cells that are increased in
response to TGFb1.
Reductions in BM-BCP in TGFb1
2/2 mice were
unanticipated because TGFb had been previously shown
to have inhibitory effects upon the B lineage in vitro (Lee
et al., 1987; Kincade et al., 1989; Lee et al., 1989;
Rehmann and LeBien, 1994; Kee et al., 2001). The
reductions in vivo may thus be due to an unrecognized
necessity for a TGFb receptor signal directly upon B
lineage cells. Alternatively, effects secondary to the
TGFb1 deﬁciency, e.g. soluble factors produced by
inﬁltrating inﬂammatory cells, circulating prostaglandins
or sex hormones (Kincade et al., 1989; Wang et al., 1995;
Kincade et al., 2000), which could be directly regulated by
TGFb1 or induced in response to inﬂammatory stress may
be responsible. Alterations in cellular adhesion may also
contribute to dysregulated B lymphopoiesis in the BM
(Dittel et al., 1993; Dittel and LeBien, 1995).
B cell development is apparently normal in very young
(1.5 week) TGFb1
2/2 mice and deteriorates thereafter.
FIGURE 4 Differential effects of TGFb1 on pro- versus pre-B cells. B220
þ BM cells from 4-week-old C57BL/6 mice were treated with IL7 ^ the
indicated concentrations of TGFb1. (A) Flow cytometry histograms of i.c.mHC staining within the B220
þsIgM
2 BCP gate of cells recovered at the
indicated times. Values are the percent i.c.mHC
þ within the total viable sample (^standard deviations from 3 experiments). (B) Absolute numbers of
pro-B-enriched (B220
þsIgM
2i.c.mHC
2) cells recovered overtime from one representative experiment of three. Bottom shows day 3 values on their own
scale. (C) Absolute numbers of pre-B (B220
þsIgM
2i.c.mHC
þ) cells over time from the experiment shown in B. (D) Pre-B cell growth is indicated as the
average number of cells generated per day. This was calculated as the number of cells at day 7 of culture minus the cell number at day 3 divided by 4
days. The mean ^ sample standard deviations from 3 experiments are shown. *p ¼ 0:0015 versus 0ng/ml TGFb1.
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acquired in utero or during nursing, compensating early in
life for the lack of de novo production (Letterio et al.,
1994) and delaying the onset of defects in B lymphopoie-
sis. Alternatively, BCP derived from older mice may
have a differential sensitivity to TGFb1 in comparison to
those generated earlier in life, as differences have been
observed for BCP at different stages of ontogeny (Kearney
et al., 1997; Hardy et al., 2000; Igarashi et al., 2001).
In either case, the mature B cells found in the BM and
periphery of 3- to 5-week old TGFb1
2/2 mice are likely
generated at an earlier age when B cell development is
unaffected by the TGFb1 mutation.
Thy1.2
þ BM cells were examined in TGFb1
2/2 mice
because activated T cells have been shown to be
responsible for the systemic inﬂammation that these
mice acquire (Kulkarni and Karlsson, 1993; Diebold et al.,
1995; Kulkarni et al., 1995; Borkowski et al., 1996;
Letterio et al., 1996; McCartney-Francis et al., 1997;
Nakabayashi et al., 1997; Kobayashi et al., 1999;
McLennan et al., 2000). Mac1
þ myeloid lineage BM
cells were also examined because enhanced myelopoiesis,
FIGURE 5 Differential sensitivity of BCP subsets to TGFb1. CD19
þsIgM
2 BCP from C57BL/6 mice were sort-puriﬁed into BP1
2 and large BP1
þ
subsets. The sorted cells were cultured, harvested, and phenotypedas in Fig. 4. (A) Numbersof pro-B cells derived from the BP1
2 sub-population from a
representative experiment. (B) Numbers of pre-B cells derived from the same BP1
2 sub-population. (C) Pre-B cells derived from the large, BP1
þ sub-
population. Results in A–C are representative of 3 experiments. (D) Summary of relative effects of low-dose TGFb1 upon B cell development over time
in culture. The size of each circle represents the effect of low-dose TGFb1 in IL7 as a fold change compared to IL7 alone ( ¼ 1.0). Stages of B cell
development examined in culture are on the X axis, whereas time in culture progresses from bottom-to-top on the Y axis.
D.A. KAMINSKI et al. 92an apparent consequence of TGFb1 deﬁciency (Boivin
et al., 1995; Letterio et al., 1996), correlates with
suppressed B lymphopoiesis (Buske et al., 2001; Fraker
and King, 2001). Macrophages are a component of the
cellular inﬁltrate seen in other tissues, such as the heart, in
these mice (Boivin et al., 1995; Kulkarni et al., 1995;
Letterio et al., 1996), and their activation products,
including interleukin 1 and the interferons, have been
shown to be inhibitory for BCP (Dorshkind, 1988; Wang
et al., 1995).
The analysis of T and myeloid cells in individual
TGFb1
2/2 mice indicates variable alterations in the
cellular composition of the BM; however, there was no
consistent correlation with BCP reductions. Moreover,
when TGFb1
2/2 mice are rendered deﬁcient in CD8
þ T
cells, by backcrossing to a b2-microglobulin (MHC
Class I) deﬁcient genetic background, which prevents the
T cell-mediated inﬂammatory disease, total B220
þ BM B
lineage cells are still reduced (Kobayashi et al., 1999).
This deﬁciency in B lineage cells, as in our studies, is
speciﬁc to the BM, and is not observed in the spleen. We
have attempted to address the role of the T cell-mediated
inﬂammatory response in the BCP deﬁciency by breeding
TGFb1
2/2 and TCRa
2/2 mice. However, no doubly
homozygous mutant offspring were obtained.
Another approach has been to examine B cell
development in a model where only B lineage cells are
unresponsivetoTGFb.Inmiceconditionallygene-targeted
for the TbRII subunit of the TGFb receptor speciﬁcally in
Bcells,the early Blineage cells in the BM were reportedly
unchanged in comparison to the controls (Cazac and Roe ¨s,
2000).However,theCD19credeletionsystemusedinthese
studies islessefﬁcient inlatepre-Bcells (75–80%)thanin
splenic B cells (90–95%) (Rickert et al., 1997). It is thus
unclear whether and at what efﬁciency TbRII deletion
occurs at earlier stages of B cell development, since TGFb
responsivenesswasnotexaminedintheBMBlineagecells
of these mice. However, in the periphery, where B lineage
cells had defective TGFb receptor signaling, populations
of mature B lymphocytes were increased, as were serum
levels of anti-nuclear antibodies indicating a direct
inhibitory role for TGFb on B lineage cells at later stages
(Cazac and Roe ¨s, 2000).
If BCP deﬁciencies in TGFb1
2/2 mice are due to a
requirement for a direct TGFb receptor signal on these
cells, we reasoned that using a deﬁned culture system with
rIL7 and puriﬁed BM B lineage cells from normal mice,
we could identify sub-populations that beneﬁt from
exposure to exogenous TGFb1. In IL7-containing
cultures, pro-B cell recoveries were consistently decreased
by low-dose TGFb1 treatment. An often-overlooked
population of i.c. mHC
þ pre-B cells, included in Hardy’s
Fraction B, is also reduced by TGFb1 in culture. By
contrast, the numbers of pre-B cells derived from large
BP1
þ BCP were increased. Notably, the more severe
in vivo BCP reductions in TGFb1
2/2 mice begin in
Fraction C, which corresponds to the large BP1
þ pre-B
cells in our cultures.
The effects of TGFb on cell cycle and apoptosis may
provide an alternative explanation for our in vitro data.
Pro-B cells proliferating in response to IL-7 eventually
mature into i.c. mHC
þ pre-B cells and then exit cell
cycle. At low doses, TGFb may inhibit proliferation of
the pro-B cells, which then may complete IgH chain gene
rearrangement and express mHC. This outcome would
result in the observed decrease in pro-B cells and
increase in pre-B cells. Higher doses of TGFb may
induce pro-B cell apoptosis, thus accounting for the
decrease in both pro- and pre-B cells. However, this
interpretation does not account for the net increase in
pre-B cells with low dose TGF-b in cultures initiated
with large BP1
þ cells, 90–99% of which already express
mHC.
In conclusion, TGFb1 inﬂuences B cell development in
multiplewaysincludingdirectlyinhibitingpro-Bcell/early
pre-B cell populations. The BP1
þ pre-B cells are unique
among B lineage cells in their positive response to
exogenous TGFb1. It is currently unclear why the large
pre-B cells respond to TGFb in this way. It has been
suggested that the stability of the preBCR, which varies
depending upon the mHC variable region, may regulate
cellular viability and proliferation (Melchers et al., 2000).
A pre-B cell with a well-ﬁtting preBCR would receive
proliferative/viability signals via the receptor itself, and
consequently the cell could be changed in other ways to
giveitthegreatestadvantageovercellswithapoorlyﬁtting
preBCR. Differential responsiveness to TGFb may be one
such phenotypic change and would be advantageous for
expanding the numbers of these positively selected pre-B
cells.
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